Efficacy, safety, and treatment persistence of netakimab in patients with active psoriatic arthritis in real-world clinical practice: interim results of the post-marketing safety study BCD-085-NIS-03/SIRIUS

Objective : to evaluate the efficacy, safety, and treatment persistence of netakimab (NTK) in patients with active psoriatic arthritis (PsA) in realworld clinical practice at 52 weeks of follow-up. Material and methods . This observational prospective cohort study included 149 patients with active PsA receiving NTK treatment in accordance with clinical guidelines. As of the data cut-off (April 21, 2025), the median follow-up duration was 63 weeks (range: 22–117 weeks). The primary endpoint was treatment persistence with NTK. Safety and tolerability were assessed through the documentation of adverse events (AEs). Results and discussion . By week 52, treatment persistence with NTK reached 96.0%. At the time of analysis, 12 (8.1%) out of 149 patients had discontinued NTK, with lack of efficacy reported in 9 cases. By week 52, only 2 AEs had been recorded, and just 1 was considered related to NTK. Conclusion . Over the 1-year observation period, NTK demonstrated a high treatment persistence rate, efficacy, and an acceptable safety profile in patients with PsA in real-world clinical practice.